2020
DOI: 10.1039/d0sc02221g
|View full text |Cite
|
Sign up to set email alerts
|

Probing metabolic alterations in breast cancer in response to molecular inhibitors with Raman spectroscopy and validated with mass spectrometry

Abstract: Rapid and accurate response to targeted therapies is critical to differentiate tumors that are resistant to treatment early in the regimen. In this work, we demonstrate a rapid, noninvasive, and label-free...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
29
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 20 publications
(32 citation statements)
references
References 62 publications
(57 reference statements)
2
29
0
Order By: Relevance
“…It is interesting to note that resistance to trametinib, an inhibitor of the extracellular-signal-regulated kinase (ERK) pathway, was observed in MCF-7 cells whilst MDA-MB-231 were shown to be sensitive to this drug treatment. 12 The lipid accumulating phenotype observed here builds on previously observed lipid increases in keratinocytes 36 and a range of cancer cell lines including breast, 7 pancreatic, 8 and bone cancer 10 cells upon exposure to a variety of different statins. The distinct advantage of the SRS imaging approach described here is that the characterisation of intracellular lipid droplets was determined in cells without the requirement for hydrophobic dyes for chemical contrast.…”
Section: Resultssupporting
confidence: 71%
“…It is interesting to note that resistance to trametinib, an inhibitor of the extracellular-signal-regulated kinase (ERK) pathway, was observed in MCF-7 cells whilst MDA-MB-231 were shown to be sensitive to this drug treatment. 12 The lipid accumulating phenotype observed here builds on previously observed lipid increases in keratinocytes 36 and a range of cancer cell lines including breast, 7 pancreatic, 8 and bone cancer 10 cells upon exposure to a variety of different statins. The distinct advantage of the SRS imaging approach described here is that the characterisation of intracellular lipid droplets was determined in cells without the requirement for hydrophobic dyes for chemical contrast.…”
Section: Resultssupporting
confidence: 71%
“…In addition to lipids, comprehensive metabolic adaptations of cancer cells in response to anti-cancer drugs could be investigated by studying the entire Raman spectral region [ 69 , 70 , 71 , 72 , 73 , 74 ]. El-Mashtoly et al applied Raman spectral imaging to study the effect of the epidermal growth factor receptor (EGFR) inhibitor panitumumab on cell lines expressing wild-type Kirsten-Ras (K-Ras) and oncogenic K-Ras mutations [ 70 ].…”
Section: Raman Spectroscopy As a Label-free Tool For Cancer Metabomentioning
confidence: 99%
“…Note that Raman-based techniques could be used in combination with other techniques to be capable of conducting rapid drug screening and discovery. Wen et al combined results from Raman spectroscopy with mass spectrometry, which is the gold standard in metabolomics, and characterized breast cancer responders and nonresponders to small molecule inhibitors [ 69 ].…”
Section: Raman Spectroscopy As a Label-free Tool For Cancer Metabomentioning
confidence: 99%
“…1 In the biomedical sciences, Raman spectroscopy has been used to study various diseases and cancers in many different tissues. [2][3][4][5] Such work typically uses near-infrared (NIR) excitation in the 780-840 nm range in order to increase the Raman/autofluorescence ratio.…”
Section: Introductionmentioning
confidence: 99%